Waltham, MA (PRWEB) May 20, 2015
“Persomics continues to build a portfolio of intellectual property around its core technology, and the grant of our first patents in the USA is a significant and potent milestone” says Neil Emans Ph.D., the CEO of Persomics USA Inc. and inventor of Persomics technology. “This is a secure foundation upon which to commercialize our innovative solutions for phenotypic screening, academic research and target discovery.”
“The US patents are timed well to back the launch of our beta testing program and we look forward to commercial products launching in 2015.” says Martin Svensson, CEO of Persomics AB. “We have enlisted beta testers in our key markets academic, pharmaceutical and biotech organizations who value the enabling potential of Persomics’ technology.”
US Patents 9,012,375 and 9,034,797 specifically cover the platform and methods Persomics utilizes to print their family of novel functional genomics research array products. The IP is generalizable, enabling partnerships with multiple providers of content for the arrays. Additionally, the manufacturing methods are cost effective, robust and flexible, enabling rapid response to research market requirements.
Persomics provides ImagineArraysTM, a technology that miniaturizes, accelerates and increases the scale of phenotypic screening. Researchers investigating the function of the human genome and disease are no longer limited by automation requirements or cost, but by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster. For more information, please visit persomics.com
Please send enquiries to:
Sean Moolman, Ph.D.